All In Biotech

Drug Trial Radar · NCT06617000

A Study of SCG101 TCR-T Cell Therpay in the Treatment of Subjects With Hepatitis B Virus-Related

A Phase 1, Multicenter Study of SCG101 in the Treatment of Subjects With Hepatitis B Virus-Related Hepatocellular Carcinoma

Last checked: Nov 19, 2026Latest source record: Sep 27, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

38

Planned (sponsor's estimate)

Start

Oct 25, 2022

Primary completion

Dec 31, 2025

Study completion Dec 31, 2025

Sponsor

Lead sponsor
SCG Cell Therapy Pte. Ltd.Industry
Sponsor type
Industry
First posted
Sep 27, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I clinical study aimed to assess the safety, tolerability, and efficacy of SCG101 monotherapy for patients with HBV-HCC.

Conditions

  • HCC
  • Hepatitis B Virus Related Hepatocellular Carcinoma
  • Hepatocellular Carcinoma

Interventions

  • SCG101Biological

    Infusion of HBsAg-specific TCR autologous T cells at assigned dose levels.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicity (DLT) and adverse events (AEs), including serious AEs (SAEs), cytokine release syndrome (CRS), and immune effector cell-associated neurotoxicity syndrome (ICANS).Time frame: Start of SCG101 infusion until disease progression or 12 months post infusion
  2. The preliminary clinical efficacy of SCG101, including objective response rate (ORR), disease control rate (DCR), duration of response (DoR), time to response (TTR), progression-free survival (PFS), and overall survival (OS).Time frame: Start of SCG101 infusion until disease progression or 12 months post infusion
  3. Change in pharmacodynamics markers (PD) before and after SCG101 infusionTime frame: Start of SCG101 infusion until disease progression, an average of 24 months
  4. Persistences of viral vector copy number (VCN) after SCG101 infusionTime frame: Start of SCG101 infusion until disease progression, an average of 24 months

Locations

7 sites in 1 country. Site status is shown where the registry gives one.

  • Beijing

    Beijing, Beijing Municipality, China · Recruiting

  • Guangzhou

    Guangzhou, Guangdong, China · Recruiting

  • Zhengzhou

    Zhengzhou, Henan, China · Recruiting

  • Changchun

    Changchun, Jilin, China · Recruiting

  • Shenyang

    Shenyang, Liaoning, China · Recruiting

  • Ji'nan

    Ji'nan, Shandong, China · Recruiting

  • Shanghai

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.